Navigation Links
Sugammadex in Medical News

Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible

... Publication of Comparative Study Shows sugammadex Provides Significantly Faster Reversal of Profound...sthesiology (Vol. 109, No. 5)(1) demonstrated that sugammadex produced a significantly more rapid recovery from ...the median time to recovery was 2.7 minutes in the sugammadex group versus 49.0 minutes in the neostigmine group...
Sugammadex in Medical Technology

U.S. FDA Issues Action Letter for Sugammadex

KENILWORTH, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug Administration (FDA) has issued a "not-approvable" letter for sugammadex sodium injection for the reversal of muscle relaxation during general anesthesia. ...

European Union's CHMP Issues Positive Opinion on Sugammadex

Anesthesiologists to have new tool that works within minutes, upon European approval KENILWORTH, N.J., June 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that the Committee for Medicinal Products for Human Use (CHMP) of the Eu...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine

OSS, the Netherlands, June 11, 2007-Sugammadex - the novel selective relaxant binding agent (SRBA) being developed by Organon, the human healthcare business unit of Akzo Nobel - demonstrated in a Phase III pivotal trial a 9-12 times faster reversal of neuromuscular blockade as compared to neostigmi...

Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine

OSS, The Netherlands, June 11, 2007 /PRNewswire/ -- Sugammadex - the novel selective relaxant binding agent (SRBA) being developed by Organon, the human healthcare business unit of Akzo Nobel - demonstrated in a Phase III pivotal trial a 9-12 times faster reversal of neuromuscular blockade as comp...

Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)

...s recommended to monitor the recovery of neuromuscular blockade. The use of sugammadex in patients with severe renal impairment is not recommended. In clinical ...duals, allergic-like reactions (i.e. flushing, erythematous rash) following sugammadex were reported. For full Prescribing Information please go to http://www....

BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union

...(moderate block) patients were administered either sugammadex or neostigmine plus glycopyrrolate. In the AURORA ... a TOF ratio of 0.9 occurred in 1.4 minutes in the sugammadex group compared to 17.6 minutes in the neostigmine/... were randomized to receive either rocuronium plus sugammadex or the rapid-onset, short- duration muscle relaxan...

FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent

...decision on approval is made. Upon FDA approval, sugammadex will be the first and only selective relaxant bind...duced by rocuronium and vecuronium within minutes. sugammadex allows for flexible dosing of muscle relaxation ag...e used. We will continue to work with FDA to bring sugammadex to the U.S. market as soon as possible so that ane...

Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia

... SAN FRANCISCO, Oct. 16 /PRNewswire/ -- sugammadex -- the novel selective relaxant binding agent (SRB...e Signal trial compared the efficacy and safety of sugammadex and neostigmine/glycopyrrolate for the reversal of...Spectrum trial compared the efficacy and safety of sugammadex for reversal of profound rocuronium-induced neurom...
Sugammadex in Biological Technology

Schering-Plough Announces Sugammadex New Drug Application Filed in Japan

KENILWORTH, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) announced that Nippon Organon K.K., now part of Schering-Plough, has filed a New Drug Application with the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking marketing approval for its nov...

Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA

KENILWORTH, N.J., Jan. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the company's New Drug Application (NDA) for sugammadex. Sugammadex is specifically designed to...

Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year

...the U.S. Food and Drug Administration (FDA); and -- Filing regulatory submissions for important new agents and indications, which now include sugammadex and asenapine from Organon. "Schering-Plough now has four full years of accomplishments since we began this transformation," said Hassan. "In that t...

Schering-Plough Completes Acquisition of Organon BioSciences

...anon), an oral contraceptive; * ORG 50081 (from Organon), for the treatment of insomnia and potentially for hot flashes in menopausal women; * sugammadex (from Organon), for the reversal of neuromuscular blockade used as part of general anesthesia during surgical procedures; * Tablet-based subling...
Other Tags
(Date:12/15/2014)... December 15, 2014 Cancer researchers have ... underlying genetic causes of deadly malignant pleural mesothelioma. Surviving ... on their website. Click here to read it ... of Hawaii Cancer Center, and New York’s Langone Medical ... pleural mesothelioma patients in an effort to pinpoint ...
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
(Date:12/15/2014)... 2014 In support of high-quality ... to restrictive state laws that may have unintended ... important area of public health policy. , The ... Integrity of Independent Review, contends that state legislation ... peer review determinations can result in subpar outcomes ...
Breaking Medicine News(10 mins):Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
Other Contents